Antimuscarinic therapy – what is new?

As overactive bladder (OAB) is highly prevalent and greatly impacts quality of life (QoL), effective therapeutic options are a welcome addition to the treatment algorithm. Recent evidence suggests that newer antimuscarinic agents are not only superior to placebo in the treatment of OAB, but may also have a role in treating OAB in the elderly and improve nocturia and sleep quality. While most adverse events (AEs) exceed those of placebo, cessation of therapy is infrequent.